NEW YORK, March 14, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on AMAG, IDXX, AZN, and CPHI which can be accessed for free by signing up to www.wallstequities.com/registration. On Tuesday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session
Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc.'s stock finished Tuesday's session 1.71% lower at $20.10. A total volume of 822,035 shares was traded. The Company's shares have advanced 55.21% in the past month and 39.58% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 24.82% and 19.69%, respectively. Furthermore, shares of AMAG Pharma, which manufactures, develops, and commercializes therapeutics for women's health, anemia management, and cancer supportive care in the US, have a Relative Strength Index (RSI) of 63.29.
On February 15th, 2018, research firm Janney upgraded the Company's stock rating from 'Neutral' to 'Buy'. Get the full research report on AMAG for free by clicking below at:
Shares in Westbrook, Maine headquartered IDEXX Laboratories Inc. ended at $204.53, up 0.09% from the last trading session. The stock recorded a trading volume of 441,010 shares. The Company's shares have gained 18.26% in the last month, 27.38% over the previous three months, and 34.91% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 13.57% and 24.44%, respectively. Moreover, shares of IDEXX Labs, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide, have an RSI of 75.88. IDXX's complimentary research coverage is a few simple steps away at:
Cambridge, the UK headquartered AstraZeneca PLC's stock ended yesterday's session 0.09% lower at $33.82 with a total trading volume of 4.00 million shares, which was above its three months average volume of 3.88 million shares. The Company's shares have advanced 12.47% in the last twelve months. The stock is trading above its 200-day moving average by 1.30%. Additionally, shares of AstraZeneca, which discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide, have an RSI of 47.26. Are you already registered with Wall St. Equities? Do so now for free, and get the report on AZN at:
China Pharma Holdings
On Tuesday, shares in Haikou, China headquartered China Pharma Holdings Inc. recorded a trading volume of 221,822 shares. The stock finished the day 0.54% higher at $0.37. The Company's shares have advanced 34.47% in the last month, 117.53% in the previous three months, and 42.23% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 3.67% and 59.02%, respectively. Furthermore, shares of China Pharma, which develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in China, have an RSI of 47.14. Aspiring Member, please take a moment to register below for your free research report on CPHI at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-healthcare-stocks----amag-pharma-idexx-labs-astrazeneca-and-china-pharma-300613768.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All